Kudo, Shun
Uchida, Takahito
Nishida, Hana
Takamiya, Akihiro
Kikuchi, Toshiaki
Yamagata, Bun
Mimura, Masaru
Hirano, Jinichi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21dm0307102h0003)
Japan Society for the Promotion of Science (17K10315)
Article History
Received: 26 September 2022
Accepted: 3 April 2023
First Online: 11 April 2023
Declarations
:
: This study was approved by the ethics committee of Keio University School of Medicine, Tokyo, Japan. The waiver for consent to participate is provided by the ethics committee of Keio University School of Medicine, Tokyo, Japan. We further confirm that all methods were employed in accordance with relevant guidelines and regulations.
: Not applicable.
: TU has received grants from SENSHIN Medical Research Foundation (Osaka, Japan) within the past two years. BY has received grants from Brain Energy Inc (Tokyo, Japan) within the past two years. MM has received speaker’s honoraria from Biogen Japan, Byer Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Demant Japan, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, H.U. Frontier, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Teijin Pharma, and Viatris within the past two years. Also, he received grants from Daiichi Sankyo, Eisai, Fronteo, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura within the past two years outside the submitted work. JH has received speaker’s honoraria from Dainippon-Sumitomo Pharma within the past two years. All other authors declare that they have no competing interests.